Skip to Content

ADMA Biologics, Inc.

Securities Class Action

  • Date:
  • 3/27/2026
  • Company Name:
  • ADMA Biologics, Inc.
  • Stock Symbol:
  • ADMA
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigato   a nationally recognized stockholder rights law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) on behalf of ADMA stockholders. Our investigation concerns whether ADMA has violated the federal securities laws and/or engaged in other unlawful business practices.


On March 24, 2026, Culper Research published a short report on ADMA, alleging that "ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor" and "estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported."

Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on March 24, 2026.


If you purchased or otherwise acquired ADMA Biologics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in ADMA Biologics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: